Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer Patrick ReimannThomas Winder short review 13 November 2023 Pages: 225 - 229
Focal therapy in intermediate- and high-risk prostate cancer Nicolai A. HuebnerStephan KornShahrokh F. Shariat short review Open access 10 November 2023 Pages: 247 - 250
Renal crystal-storing histiocytosis successfully treated with bortezomib-based regimen Poornima TadkalSiddini VishwanathMallikarjun Kalashetty case report 07 November 2023 Pages: 57 - 62
Management of malignant hypercalcemia in cancer patients—a short review Clemens PetraschPetra MaricsThomas Spanberger short review 03 November 2023 Pages: 263 - 267
Genetic testing and management of prostate cancer patients with pathogenic germline variants Katharina ReiterMelanie R. Hassler short review Open access 03 November 2023 Pages: 51 - 56
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction Sophie Roider-SchurSybille MachatLeopold Öhler case report 27 October 2023 Pages: 242 - 245
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma Angela Djanani short review Open access 27 October 2023 Pages: 234 - 236
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment Sazan RasulStephan Korn short review Open access 19 October 2023 Pages: 251 - 254
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma Aysegül Ilhan-MutluEwald Wöll short review Open access 19 October 2023 Pages: 237 - 241
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis Giuseppe A. CollocaAntonella Venturino original report 17 October 2023 Pages: 146 - 151
Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer Julia M. BergerPia GattingerMatthias Preusser special report Open access 13 October 2023 Pages: 63 - 66
Long-term survival and follow-up care after cancer in Austria Alexandra Böhm editorial 14 September 2023 Pages: 148 - 148
American Society of Hematology meeting update Dominik Wolf editorial 14 September 2023 Pages: 145 - 145
Brief update on systemic therapies in myeloproliferative neoplasms Janine SteichenDominik Wolf short review Open access 31 August 2023 Pages: 140 - 145
Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors Petar Popov short review Open access 29 August 2023 Pages: 255 - 258
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients Ronald HereggerRichard Greil short review Open access 28 August 2023 Pages: 259 - 262
New developments in radiation oncology for head and neck cancers Christoph ReslPetra GeorgCarmen Döller short review Open access 23 August 2023 Pages: 170 - 175
ASCO 2023: new treatment options in CNS tumors Josef Pichler short review 17 August 2023 Pages: 222 - 224
Late complications after oncological therapy Marco Hassler short review 15 August 2023 Pages: 180 - 184
FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting Verena PetzerDominik Wolf short review Open access 15 August 2023 Pages: 152 - 155
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ASCO Hybrid Congress , 2nd – 6th June 2023 Congress Report ASCO 2023: Lung Cancer 08 August 2023 Pages: 89 - 104
A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES. Report from the American Society of Clinical Oncology (ASCO) Annual Meeting (hybrid), 2nd-6th June 2023, European Hematology Association (EHA) 2023 Congress (hybrid), 8th-11th June 2023, and the 17th International Conference on Malignant Lymphoma (ICML) 2023 Congress (hybrid), 13th-17th June 2023 Congress Report ASCO, EHA, ICML 2023 08 August 2023 Pages: 105 - 124
Emerging molecular drugs for the treatment of gastroesophageal tumors Aysegül Ilhan-Mutlu leading article Open access 07 August 2023 Pages: 198 - 199
Aggressive B cell lymphomas—highlights from ASH 2022 Michael Panny short review 02 August 2023 Pages: 149 - 151
Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma Florian KocherAndreas Seeber short review Open access 28 July 2023 Pages: 176 - 179
Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer Dominik A. BarthMartin Pichler short review 25 July 2023 Pages: 189 - 192
Lipid nanoparticles in the treatment of lung cancer—hype or hope? Anna MairFabienne NoceraAndreas Pircher short review Open access 24 July 2023 Pages: 193 - 197
ASH highlights 2022—multiple myeloma Lina Z. RüsingHermine AgisMaria Krauth short review Open access 22 July 2023 Pages: 160 - 164
Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin Kaoutar MelianiNoufissa Alami DribiRhyzlane Berrady case report 05 July 2023 Pages: 208 - 212
ASH 2022—new developments in acute myeloid leukemia Michael Pfeilstöcker review 20 June 2023 Pages: 156 - 159
Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches Simon UdovicaKathrin Strasser-Weippl short review 08 May 2023 Pages: 125 - 128
ESMO update: upper gastrointestinal cancer Elisabeth S. BergenAysegül Ihan-Mutlu short review Open access 05 May 2023 Pages: 105 - 107
ESMO 2022 personal non-small lung cancer (NSCLC) highlights Lena HorvathGeorg Pall short review 05 May 2023 Pages: 97 - 99
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment Christiane G. Mutz-RablPeter KoelblingerLukas Koch short review Open access 03 May 2023 Pages: 108 - 112
Lessons learned in adjuvant colorectal cancer Theresa SchmalfussHossein Taghizadeh short review Open access 28 April 2023 Pages: 113 - 115
How the long-term follow-up is organized in young adult survivors of childhood cancer Edit BardiLeo KagerWolfgang Holter short review Open access 27 April 2023 Pages: 185 - 188
Molecular pathology of colorectal cancer Petar NoackRupert Langer review Open access 27 April 2023 Pages: 116 - 121
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), October 15th – 19th, 2022, Barcelona Congress Report EANM 2022 26 April 2023 Pages: 75 - 88
A CONGRESS DIGEST ON NEUROENDOCRINE TUMORS. Report from the North American Neuroendocrine Tumor Society (NANETS) Annual Medical Symposium, 27th – 29th October 2022, Washington Congress Report NANETS 2022 26 April 2023 Pages: 65 - 74
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report Clemens PetraschSimon UdovicaAndrea Kaufmann-Keck case report 20 April 2023 Pages: 122 - 124
Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting Maximilian Marhold short review Open access 20 April 2023 Pages: 94 - 96
A GLOBAL CONGRESS DIGEST ON ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO Immuno-Oncology Congress, 7th – 9th December 2022 Congress Report ESMO Immuno-Oncology 2022 20 April 2023 Pages: 53 - 64
A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES AND AML. Report from the American Society of Hematology (ASH) Annual Meeting, December 10–13, 2022 Congress Report ASH 2022 18 April 2023 Pages: 29 - 52
Assessment of nutritional status using objective and subjective methods in Greek patients with cancer Konstantina VamvakariIliana EvangelouOdysseas Androutsos original report Open access 22 March 2023 Pages: 200 - 207
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors Maximilian J. MairAnna S. Berghoff short review Open access 20 March 2023 Pages: 100 - 104
